汶川地震救援人员创伤后应激反应特征的初步研究

目的:探讨5.12汶川地震军队救援人员创伤后应激损伤状况。方法:采用创伤后压力诊断量表、焦虑自评量表、抑郁自评量表和匹兹堡睡眠质量问卷,在地震爆发后65天左右,对107名执行运输遗体任务的官兵进行了测量。结果:PTSD症状轻度的占84%,中重度的占15%。其中症状在1个月内消失的占63%。从症状的分布来看,闯入性回忆占36.4%,回避29.9%,过度警觉29.9%,焦躁不安或易怒37.4%,入睡困难、睡眠易醒或早醒43.9%,难以集中注意力45.8%,对重要的活动兴趣下降32.7%。救援人员抑郁症状得分低于全国常模水平;焦虑自评量表得分与全国常模差异不显著。睡眠质量差的占72%,以入睡时间长和日间功能降低为主。结论:担任遗体运输的救援官兵在救援早期普遍存在创伤后应激反症状,症状程度较轻,多数在1个月内消失,焦虑和抑郁症状水平的总体状况也比较低,但普遍存在睡眠质量差的问题,并且直接影响到日间功能。     

冠心病介入术前患者睡眠质量及相关因素研究

目的:探讨冠心病介入治疗患者术前睡眠质量及其影响因素。方法:采用一般状况调查表、匹兹堡睡眠质量指数(PSQI)量表、焦虑自评量表(SAS)、抑郁自评量表(SDS)、社会支持评定量表(SSRS)对2013年7月至2014年1月在某院心内科接受介入治疗的392例冠心病患者进行问卷调查。结果:发放问卷410份,回收有效问卷392份,有效率为95.6%。392例患者中287例存在睡眠质量问题,总发生率为73.2%,PSQI总分为9.88±3.63。相关因素分析显示年龄、性别、婚姻状况、焦虑、抑郁和社会支持6项是冠心病介入治疗术前患者睡眠质量的预测因素。结论:冠心病介入治疗患者术前睡眠质量较差,并受多种因素影响。     

癫痫患者睡眠障碍特点及失眠症状与认知功能、焦虑抑郁的关系研究

摘要 目的：探讨癫痫患者的睡眠障碍特点,分析失眠症状与认知功能、焦虑抑郁的关系。方法：纳入我院2018年2月至2020年6月收治的120例癫痫患者为研究对象（癫痫组）,依据失眠严重指数量表（ISI）总分将其分为失眠组（ISI总分≥15分）与无失眠组（ISI总分＜15分）。另选取50例健康体检者为健康对照组,探讨癫痫患者睡眠障碍特点,分析失眠症状与认知功能和焦虑抑郁的关系。结果：癫痫组匹兹堡睡眠质量指数量表（PSQI）评分（4.45±1.26）分、ISI评分（12.35±5.63）分、Epworth嗜睡量表（ESS）评分（6.32±3.54）分均高于健康对照组的（3.11±1.03）分、（9.62±5.14）分、（5.12±3.06）分,差异有统计学意义（P＜0.05）。癫痫失眠者占19.17%（23/120）,无失眠者占80.83%（97/120）。失眠组病程、ISI评分、发作类型与无失眠组比较差异有统计学意义（P＜0.05）。失眠组蒙特利尔认知评估量表(MoCA)总分低于无失眠组,贝克抑郁量表第2版（BDI-Ⅱ）评分、贝克焦虑量表（BAI）评分高于无失眠组,差异有统计学意义（P＜0.05）。Pearson相关分析显示：癫痫患者ISI总分与MoCA总分呈负相关（P＜0.05）,与BDI-Ⅱ评分、BAI评分呈正相关（P＜0.05）。结论：癫痫患者多存在睡眠障碍,且认知功能、焦虑抑郁症状与失眠症状密切相关。     

焦虑、抑郁及社会支持情况对短暂性脑缺血发作患者睡眠的影响

目的:讨论焦虑、抑郁和社会支持情况对短暂性脑缺血患者睡眠的影响情况。方法:将2012年1月至2014年1月于我院治疗的164名短暂性脑缺血患者为研究对象,采用社会支持评定量表SSRS、自评焦虑量表SAS、匹兹堡睡眠指数PSQI及自评抑郁量表SDS评估病人的抑郁、焦虑与社会支持情况对患者的影响,并分析相关性。在对患者进行一个月的治疗过程中,对伴有焦虑及抑郁症状的患者给予盐酸舍曲林片,并考察药物治疗对患者睡眠质量的影响情况。结果:164名患者中出现焦虑的几率为37.4%,出现抑郁的几率为18.9%,二者同时出现的几率为12.8%,存在睡眠障碍的患者约占68.4%,匹兹堡睡眠指数与自评焦虑量指数、自评抑郁量指数与社会支持评定量的主观支持与患者对支持和利用得分均存在相关性(r=0.66、0.53、-0.39,-0.40,P0.05),且差异有统计学意义。对采集的数据进行多因素回归分析,结果显示,焦虑、抑郁、社会主观支持和患者对支持的利用度是影响睡眠的重要因素。通过Logistic回归分析,结果显示患者对支持利用度的增加及自评焦虑量指数、自评抑郁量指数与发作次数的减少有利于改善患者的睡眠障碍(OR=0.221、2.412、1.938、0.321,P0.05)。结论:抑郁、焦虑和社会支持是导致短暂性脑缺血患者存在睡眠障碍的重要因素,对三者情况进行改善可辅助药物治疗,改善患者睡眠质量。     

Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease

Background

Frequent exacerbations induce a high burden to Chronic Obstructive Pulmonary Disease (COPD). We investigated the course of exacerbations in the published COSMIC study that investigated the effects of 1-year withdrawal of fluticasone after a 3-month run-in treatment period with salmeterol/fluticasone in patients with COPD.

Methods

In 373 patients, we evaluated diary cards for symptoms, Peak Expiratory Flow (PEF), and salbutamol use and assessed their course during exacerbations.

Results

There were 492 exacerbations in 224 patients. The level of symptoms of cough, sputum, dyspnea and nocturnal awakening steadily increased from 2 weeks prior to exacerbation, with a sharp rise during the last week. Symptoms of cough, sputum, and dyspnea reverted to baseline values at different rates (after 4, 4, and 7 weeks respectively), whereas symptoms of nocturnal awakening were still increased after eight weeks. The course of symptoms was similar around a first and second exacerbation. Increases in symptoms and salbutamol use and decreases in PEF were associated with a higher risk to develop an exacerbation, but with moderate predictive values, the areas under the receiver operating curves ranging from 0.63 to 0.70.

Conclusions

Exacerbations of COPD are associated with increased symptoms that persist for weeks and the course is very similar between a first and second exacerbation. COPD exacerbations are preceded by increased symptoms and salbutamol use and lower PEF, yet predictive values are too low to warrant daily use in clinical practice.     

冠心病患者术前睡眠质量调查及影响因素分析

目的:研究心血管外科冠心病患者术前的睡眠质量、焦虑情况及其影响因素。方法:采用匹兹堡睡眠质量指数(PSQI)量表、医院焦虑抑郁量表(HADS)和自制的影响睡眠质量因素调查表对入选的100例患者进行问卷调查,对问卷结果进行统计学分析。结果:1住院患者术前10天PSQI总分为9.42±4.90,术前1天PSQI总分为12.39±3.93。2患者术前1天焦虑分数明显升高,且焦虑越重,睡眠质量越差。3影响患者术前睡眠质量的影响因素主要有对手术的焦虑感、术前准备操作、医护人员行为、身体不适感、环境噪音等。结论:心脏外科住院患者术前睡眠质量较差,与焦虑心理显著相关,并受到多种因素的影响,应加强对这些因素的控制,提高其睡眠质量,促进手术的顺利进行。     

ASSOCIATIONS BETWEEN CHRONOTYPE,SLEEP QUALITY,SUICIDALITY, AND DEPRESSIVE SYMPTOMS IN PATIENTS WITH MAJOR DEPRESSION AND HEALTHY CONTROLS

Research interest concerning associations between sleep characteristics and suicidality in psychopathology has been growing. However, possible linkages of suicidality to sleep characteristics in terms of sleep quality and chronotypes among depressive patients have not been well documented. In the current study, the authors investigated the possible effects of sleep quality and chronotype on the severity of depressive symptoms and suicide risk in patients with depressive disorder and healthy controls. The study was conducted on 80 patients clinically diagnosed with major depression and 80 healthy subjects who were demographically matched with the patient group. All participants completed a questionnaire package containing self-report measures, including the Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI), Morningness–Eveningness Questionnaire (MEQ), and Suicide Ideation Scale (SIS), and subjects were interviewed with the suicidality section of the Mini-International Neuropsychiatric Interview (MINI). Results are as follows: (a) logistic regression analyses revealed that poor sleep quality and depression symptom severity significantly predicted onset of major depression; (b) morningness-type circadian rhythm may play as a significant relief factor after onset of major depression; (c) sleep variables of chronotype and sleep quality did not significantly predict suicide ideation after controlling for depressive symptoms in the major depression group; and (d) suicide ideation and poor sleep quality were antecedents of depression symptom severity in patients with major depression, and in healthy controls. Findings are discussed under the theoretical assumptions concerning possible relations between chronotype, sleep quality, depression, and suicidality. (Author correspondence: dryavuzselvi@yahoo.com)     

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week,randomized, placebo-controlled AUGMENT COPD study

Background

Combining two long-acting bronchodilators with complementary mechanisms of action may provide treatment benefits to patients with chronic obstructive pulmonary disease (COPD) that are greater than those derived from either treatment alone. The efficacy and safety of a fixed-dose combination (FDC) of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol fumarate, a long-acting β₂-agonist, in patients with moderate to severe COPD are presented.

Methods

In this 24-week double-blind study, 1692 patients with stable COPD were equally randomized to twice-daily treatment with FDC aclidinium 400 μg/formoterol 12 μg (ACL400/FOR12 FDC), FDC aclidinium 400 μg/formoterol 6 μg (ACL400/FOR6 FDC), aclidinium 400 μg, formoterol 12 μg, or placebo administered by a multidose dry powder inhaler (Genuair^®/Pressair^®)*. Coprimary endpoints were change from baseline to week 24 in 1-hour morning postdose FEV₁ (FDCs versus aclidinium) and change from baseline to week 24 in morning predose (trough) FEV₁ (FDCs versus formoterol). Secondary endpoints were change from baseline in St. George’s Respiratory Questionnaire (SGRQ) total score and improvement in Transition Dyspnea Index (TDI) focal score at week 24. Safety and tolerability were also assessed.

Results

At study end, improvements from baseline in 1-hour postdose FEV₁ were significantly greater in patients treated with ACL400/FOR12 FDC or ACL400/FOR6 FDC compared with aclidinium (108 mL and 87 mL, respectively; p < 0.0001). Improvements in trough FEV₁ were significantly greater in patients treated with ACL400/FOR12 FDC versus formoterol (45 mL; p = 0.0102), a numerical improvement of 26 mL in trough FEV₁ over formoterol was observed with ACL400/FOR6 FDC. Significant improvements in both SGRQ total and TDI focal scores were observed in the ACL400/FOR12 FDC group at study end (p < 0.0001), with differences over placebo exceeding the minimal clinically important difference of ≥4 points and ≥1 unit, respectively. All treatments were well tolerated, with safety profiles of the FDCs similar to those of the monotherapies.

Conclusions

Treatment with twice-daily aclidinium 400 μg/formoterol 12 μg FDC provided rapid and sustained bronchodilation that was greater than either monotherapy; clinically significant improvements in dyspnea and health status were evident compared with placebo. Aclidinium/formoterol FDC may be an effective and well tolerated new treatment option for patients with COPD.

Trial registration

Clinicaltrials.gov {"type":"clinical-trial","attrs":{"text":"NCT01437397","term_id":"NCT01437397"}}NCT01437397.*Registered trademarks of Almirall S.A., Barcelona, Spain; for use within the US as Pressair^® and Genuair^® within all other licensed territories.

Electronic supplementary material

The online version of this article (doi:10.1186/s12931-014-0123-0) contains supplementary material, which is available to authorized users.     

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change

Background

Little is known about factors that determine health status decline in clinical trials of COPD.

Objectives

To examine health status changes over 3 years in the TORCH study of salmeterol+fluticasone propionate (SFC) vs. salmeterol alone, fluticasone propionate alone or placebo.

Methods

St George''s Respiratory Questionnaire (SGRQ) was administered at baseline then every 6 months.

Measurements and Main Results

Data from 4951 patients in 28 countries were available. SFC produced significant improvements over placebo in all three SGRQ domains during the study: (Symptoms -3.6 [95% CI -4.8, -2.4], Activity -2.8 [95% CI -3.9, -1.6], Impacts -3.2 [95% CI -4.3, -2.1]) but the pattern of change over time differed between domains. SGRQ deteriorated faster in patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages III & IV relative to GOLD stage II (p < 0.001). There was no difference in the relationship between deterioration in SGRQ Total score and forced expiratory volume in one second (FEV₁) decline (as % predicted) in men and women. Significantly faster deterioration in Total score relative to FEV₁ % predicted was seen in older patients (≥ 65 years) and there was an age-related change in Total score that was independent of change in FEV₁. The relationship between deterioration in FEV₁ and SGRQ did not differ in different world regions, but patients in Asia-Pacific showed a large improvement in score that was unrelated to FEV₁ change.

Conclusions

In addition to treatment effects, health status changes in clinical trials may be influenced by demographic and disease-related factors. Deterioration in health status appears to be fastest in older persons and those with severe airflow limitation.

Trial Registration

ClinicalTrials.gov: {"type":"clinical-trial","attrs":{"text":"NCT00268216","term_id":"NCT00268216"}}NCT00268216     

The characterization of a novel V1b antagonist lead series

The SAR around a V1b antagonist HTS hit 3 was explored to produce a series of thiazole sulfonamides as a lead series with selectivity over the related V1 and oxytocin receptors.     

COPD and disease-specific health status in a working population

Background

It has been debated whether treatment should be started early in subjects with mild to moderate COPD. An impaired health status score was associated with a higher probability of being diagnosed with COPD as compared with undiagnosed COPD.

Purpose

To investigate the health status in a healthy working population, to determine reference scores for healthy non-smoking subjects, and to investigate the relationship between their health status and airflow limitation.

Methods

A total of 1333 healthy industrial workers aged ≥40 years performed spirometry and completed the St. George’s Respiratory Questionnaire (SGRQ) and the COPD Assessment Test (CAT).

Results

The prevalence of COPD defined by the fixed ratio of the forced expiratory volume in one second (FEV₁)/forced vital capacity (FVC) was 10.9%, and the prevalence defined by the Lower Limit of Normal was 5.0%. All SGRQ and CAT scores were skewed to the milder end. In 512 non-smoking subjects with normal spirometry, the mean SGRQ score was 5.7, and the mean CAT score was 5.8. In 145 people with COPD defined by the fixed ratio, the mean SGRQ score was 7.9, with a zero score in 6.9% of the subjects. Using the CAT, the mean score was 7.3, with 7.6% of the scores being zero. The scores in patients identified using the Lower Limit of Normal approach were: SGRQ 8.4 (13.4% had a score of zero) and CAT 7.4 (13.4% had a score of zero). Although the 95th percentiles of the Total, Symptoms, Activity, and Impact scores of the SGRQ and CAT sores were 13.8, 34.0, 23.4, 7.2 and 13.6 in the 512 healthy non-smoking subjects, respectively, they were also distributed under their upper limits in over 80% of the COPD subjects.

Conclusion

The COPD-specific health status scores in a working population were good, even in those with spirometrically diagnosed COPD. All scores were widely distributed in both healthy non-smoking subjects and in subjects with COPD, and the score distribution overlapped remarkably between these two groups. This suggests that symptom-based methods are not suitable screening tools in a healthy general population.     

Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials

Background

Symptomatic relief is an important treatment goal for patients with COPD. To date, no diary for evaluating respiratory symptoms in clinical trials has been developed and scientifically-validated according to FDA and EMA guidelines. The EXACT – Respiratory Symptoms (E-RS) scale is a patient-reported outcome (PRO) measure designed to address this need. The E-RS utilizes 11 respiratory symptom items from the existing and validated 14-item EXACT, which measures symptoms of exacerbation. The E-RS total score quantifies respiratory symptom severity, and 3 domains assess breathlessness, cough and sputum, and chest symptoms.

Methods

This study examined the performance of the E-RS in each of 3 controlled trials with common and unique validation variables: one 6-month (N = 235, US) and two 3-month (N = 749; N = 597; international). Subjects completed the E-RS as part of a daily eDiary. Tests of reliability, validity, and responsiveness were conducted in each dataset.

Results

In each study, RS-Total score was internally consistent (Cronbach α) (0.88, 0.92, 0.92) and reproducible (intra-class correlation) in stable patients (2 days apart: 0.91; 7 days apart: 0.71, 0.74). RS-Total scores correlated significantly with the following criterion variables (Spearman’s rho; p < 0.01, all comparisons listed here): FEV₁% predicted (−0.19, −0.14, −0.15); St. George’s Respiratory Questionnaire (SGRQ) (0.65, 0.52, 0.51); Breathlessness, Cough, and Sputum Scale (BCSS) (0.89, 0.89); modified Medical Research Council dyspnoea scale (mMRC) (0.40); rescue medication use (0.43, 0.42); Functional Performance Inventory Short-Form (FPI-SF) (0.43); 6-minute walk distance (6-MWT) (−0.30, −0.14) and incremental shuttle walk (ISWT) (−0.18) tests. Correlations between these variables and RS-Breathlessness, RS-Cough and Sputum, RS-Chest Symptoms scores supported subscale validity. RS-Total, RS-Breathlessness, and RS-Chest Symptoms differentiated mMRC levels of breathlessness severity (p < 0.0001). RS-Total and domain scores differentiated subjects with no rescue medication use and 3 or more puffs (p < 0.0001). Sensitivity to changes in health status (SGRQ), symptoms (BCSS), and exercise capacity (6MWT, ISWT) were also shown and responder definitions using criterion- and distribution-based methods are proposed.

Conclusions

Results suggest the E-RS is a reliable, valid, and responsive measure of respiratory symptoms of COPD suitable for use in natural history studies and clinical trials.

Trial registration

MPEX: {"type":"clinical-trial","attrs":{"text":"NCT00739648","term_id":"NCT00739648"}}NCT00739648; AZ1: {"type":"clinical-trial","attrs":{"text":"NCT00949975","term_id":"NCT00949975"}}NCT00949975; AZ 2: {"type":"clinical-trial","attrs":{"text":"NCT01023516","term_id":"NCT01023516"}}NCT01023516

Electronic supplementary material

The online version of this article (doi:10.1186/s12931-014-0124-z) contains supplementary material, which is available to authorized users.     

艾司西酞普兰联合唑吡坦对失眠障碍患者睡眠质量、焦虑抑郁状态及血清神经递质的影响

摘要 目的：探讨艾司西酞普兰联合唑吡坦对失眠障碍患者睡眠质量、焦虑抑郁状态及血清神经递质的影响。方法：选取2018年1月~2020年12月期间我院收治的失眠障碍患者100例为研究对象。根据随机数字表法分为对照组（唑吡坦治疗,n=50）和研究组（对照组的基础上联合艾司西酞普兰治疗,n=50）,比较两组患者睡眠质量、焦虑抑郁状态、血清神经递质及不良反应情况。结果：治疗4周后,研究组睡眠效率高于对照组,睡眠总时间长于对照组,醒觉时间、入睡时间短于对照组（P<0.05）。治疗4周后,研究组匹兹堡睡眠质量指数（PSQI）、汉密顿抑郁评估量表（HAMD）、汉密顿焦虑评估量表(HAMA)低于对照组（P<0.05）。治疗4周后,研究组5-羟色胺（5-HT）、r-氨基丁酸（GABA）水平高于对照组,去甲肾上腺素（NE）水平低于对照组（P<0.05）。两组不良反应发生率比较无差异（P>0.05）。结论：失眠障碍患者接受唑吡坦、艾司西酞普兰联合治疗,可有效改善患者焦虑抑郁状态、睡眠质量以及血清神经递质水平,安全性较好。     

艾司西酞普兰联合心理疗法对焦虑症患者睡眠质量、生活质量和血清神经递质水平的影响

目的:探讨艾司西酞普兰联合心理疗法对焦虑症患者睡眠质量、生活质量和血清神经递质水平的影响.方法:选取2017年7月～2020年3月期间我院收治的焦虑症患者117例,随机分为对照组58例和研究组59例,对照组给予艾司西酞普兰治疗,研究组在对照组的基础上联合心理疗法,对比两组疗效、汉密尔顿焦虑量表(HAMA)、匹兹堡睡眠质...     

S- 腺苷蛋氨酸在肝病患者中抗抑郁作用的研究进展

S-腺苷蛋氨酸(S-adenosyl-L-methionine,SAMe)是一种天然分子存在于人体所有细胞中,在肝脏、肾上腺以及松果体中具有较高浓度,在大脑中亦均匀分布。S-腺苷蛋氨酸通过抗氧化自由基及促进肝细胞再生等机制对肝细胞具有多重保护作用长久以来被广泛应用于肝病所致的肝内胆汁淤积、抗肝纤维化等治疗。近年来,研究亦发现S-腺苷蛋氨酸可增加患者脑中神经元膜的流动性及促进兴奋性神经递质的产生等对改善肝病患者情绪、治疗肝病患者抑郁症等方面具有重要的双重作用。通过静脉或口服用药,均可提高患者脑脊液中SAMe浓度,对于轻、中度抑郁患者的辅助治疗,更具安全性、有效性,这为人类的\"生理-心理\"疾病的治疗带来更广阔的应用前景。现将其对肝病患者抗抑郁的作用机制及临床应用综述如下。     

S-腺苷蛋氨酸治疗胆汁淤积性肝病伴抑郁／焦虑的临床效果研究

目的：研究s-腺苷蛋氨酸治疗胆汁淤积性肝病伴抑郁／焦虑患者的临床效果。方法：选择2011年3月-2013年3月我院收治的51例不同病因的胆汁淤积性肝病（药物性肝损害13例、慢性乙型肝硬化14例、酒精性肝硬化11例、自身免疫性肝病6例、肝癌5例、胆管癌2例）并抑郁／焦虑的患者,予s-腺苷蛋氨酸1．0g治疗2周,应用SDS／SAS量表分别评估和比较治疗前后各组患者抑郁／焦虑程度的评分情况。结果：S-腺苷蛋氨酸治疗后,所有组别胆汁淤积性肝病肝病改善的临床总有效率94．12％,其中药物性肝损害、慢性乙型肝硬化、酒精性肝硬化、自身免疫性肝硬化总有效率均为100．00％,肝癌的有效率为60．00％,胆管癌的有效率为50．00％,药物性肝损害患者临床疗效与其他各组有差异（P〈0．05）;药物性肝病患者SDS和SAS评分均较治疗前显著降低（P〈0．05）。而慢性乙型肝硬化、酒精性肝硬化、自身免疫性肝病、肝癌、胆管癌患者SDS和SAS评分与治疗前相比均无统计学差异（P〉0．05）。结论：S-腺苷蛋氨酸可改善药物性胆汁淤积性肝病并轻、中度抑郁／焦虑患者的肝功能,并有效减轻其抑郁／焦虑情绪。     

S-腺苷蛋氨酸治疗胆汁淤积性肝病伴抑郁/焦虑的临床效果研究

目的:研究S-腺苷蛋氨酸治疗胆汁淤积性肝病伴抑郁/焦虑患者的临床效果。方法:选择2011年3月~2013年3月我院收治的51例不同病因的胆汁淤积性肝病(药物性肝损害13例、慢性乙型肝硬化14例、酒精性肝硬化11例、自身免疫性肝病6例、肝癌5例、胆管癌2例)并抑郁/焦虑的患者,予S-腺苷蛋氨酸1.0 g治疗2周,应用SDS/SAS量表分别评估和比较治疗前后各组患者抑郁/焦虑程度的评分情况。结果:S-腺苷蛋氨酸治疗后,所有组别胆汁淤积性肝病肝病改善的临床总有效率94.12%,其中药物性肝损害、慢性乙型肝硬化、酒精性肝硬化、自身免疫性肝硬化总有效率均为100.00%,肝癌的有效率为60.00%,胆管癌的有效率为50.00%,药物性肝损害患者临床疗效与其他各组有差异(P0.05);药物性肝病患者SDS和SAS评分均较治疗前显著降低(P0.05)。而慢性乙型肝硬化、酒精性肝硬化、自身免疫性肝病、肝癌、胆管癌患者SDS和SAS评分与治疗前相比均无统计学差异(P0.05)。结论:S-腺苷蛋氨酸可改善药物性胆汁淤积性肝病并轻、中度抑郁/焦虑患者的肝功能,并有效减轻其抑郁/焦虑情绪。     

非小细胞肺癌患者术后抑郁状况的影响因素及与生存质量和睡眠质量的相关性研究

摘要 目的：探讨非小细胞肺癌（NSCLC）患者术后抑郁状况的影响因素,分析术后抑郁与生存质量和睡眠质量的关系。方法：选取2019年1月～2021年1月在韶关市第一人民医院胸外科行手术治疗的 80例NSCLC患者,采用抑郁自评量表（SDS）评估其术后抑郁情况,根据评估结果将患者分为抑郁组（SDS评分≥50分,33例）和非抑郁组（SDS评分＜50分,47例）,单因素及多因素Logistic回归分析NSCLC患者术后抑郁的影响因素。采用肺癌患者生存质量测定量表（FACT-L）中文版（V4.0）、匹兹堡睡眠质量指数量表（PSQI）测评所有患者的生存质量和睡眠质量,Pearson相关性分析SDS评分与FACT-L、PSQI评分之间的关系。结果：抑郁组与非抑郁组间年龄、性别、文化程度、家庭收入水平、医疗费用支付方式、生活能否自理、肺癌TNM分期、术后是否并发肺炎有明显差异（P＜0.05）。进一步多因素分析显示,术后并发肺炎、肺癌TNM分期Ⅲ期、女性、大专以下文化程度是NSCLC患者术后抑郁的危险因素（P＜0.05）。抑郁组FACT-L评分低于非抑郁组,PSQI评分高于非抑郁组（P＜0.05）。SDS评分与FACT-L评分呈负相关,与PSQI评分呈正相关（P＜0.05）。结论：术后并发肺炎、肺癌TNM分期Ⅲ期、女性、文化程度低是影响NSCLC患者术后抑郁的因素,术后抑郁的发生会降低患者的生存质量和睡眠质量。     

心理护理对恶性肿瘤患者抑郁焦虑的影响

目的:探讨恶性肿瘤住院患者焦虑抑郁情绪的相关因素及心理护理干预对其的影响。方法:对158例恶性肿瘤住院患者(肿瘤组)及170例良性疾病住院患者(良性组)进行焦虑、抑郁自评(应用焦虑自评量表(SAS)、抑郁自评量表(SDS))及他评(应用汉密尔顿抑郁量表(HAMD)和汉密尔顿焦虑量表(HAMA)评分调查及统计分析;将肿瘤组患者随机分为常规护理组(对照组)、常规护理 心理护理组(护理组),通过心理护理干预,观察两组SAS、SDS、HAMD、HAMA评分变化。结果恶性肿瘤住院患者焦虑、抑郁程度明显高于良性疾病患者,差异有显著性(P<0.01)。在接受心理护理干预后,患者的焦虑抑郁评分及发生率较干预前明显下降,差异有显著性(P<0.05或0.01)。结论:恶性肿瘤患者焦虑和抑郁情绪程度及发生率高于良性疾病患者;心理护理干预可改善恶性肿瘤住院患者焦虑、抑郁情绪,有利于提高患者的生活质量及康复。